Hawaii Pacific Health
Quick facts
Phase 3 pipeline
- ranibizumab intravitreal injection · Ophthalmology
Ranibizumab works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and thereby inhibiting angiogenesis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: